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MUSC-MC Formulary System:
What Every Practictioner Needs to Know
The formulary system is a process whereby the professional
staff, working through the Pharmacy and Therapeutics Committee, evaluates, appraises, and selects medications that are considered to be most useful in patient care. The formulary system
is an important mechanism for
optimizing patient outcomes
while controlling expenditures.

specific preprinted order forms,
and links to the Micromedex
monograph, patient education
leaflet, and PubMed citations for
each medication. Other items pertinent to the formulary such as
links to medication use guidelines,
charts, and policies are also located with specific medication or
listed alphabetically under Drug
Information Resources.

The MUSC-MC Formulary of
Accepted Drugs is a list of approved medications and dosage
forms available for use throughout the Medical Center. The formulary is a tool that helps practitioners make rational drug therapy decisions. After careful review of current medical literature, the Pharmacy and Therapeutics Committee determines
which agents are added to and
deleted from the formulary.

Any physicain may prescribe any
unrestricted formulary medication
listed in the MUSC-MC Formulary of Accepted Drugs. Nurse
practitioners and physician assistants may prescribe formulary
medications based on their scope
of practice in accordance with
South Carolina law and based on
the individual collaborative practice agreement that each clinician
has with their supervising physician.

The formulary is accessible
online. A link can be found on
the MUSC-MC Intranet or at
www.formularyproducts.com/musc.
The online formulary contains
medications and respective formulations that are approved for
use, comments regarding restrictions, links to medication-

The Pharmacy and Therapeutics
Committee restricts the use of certain medications on the formulary.
The purpose is to ensure patient
safety and appropriate utilization.
Medications may be restricted by
physician status, physician specialty, specific patient care unit,
specific disease state, or specific
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patient population. Physicians
may prescribe formulary restricted
medications so long as the condition of the formulary restriction is
met. Nurse practitioners and physician assistants may prescribe
formulary restricted medications
within the scope of their practice
and based on the individual collaborative practice agreement, so
long as the condition of the formulary restriction is met.
Restricted medications can not be
ordered outside of the restriction
unless approval is obtained by the
Chair of the Pharmacy and Therapeutics Committee. Only attending physicians may request approval. Formulary restrictions are
noted in the online formulary and
in the pharmacy order entry system under each specific medication. Additionally, a cumulative
list of restricted medications is
available on the front page of the
online formulary.
Authority to dispense most formulary medications is delegated to
the pharmacist by the Director of
Pharmacy Services. However, the

Pharmacy and Therapeutics
Committee requires that prior to
dispensing high-cost formulary
medications, a second-level administrative approval must be
obtained. A high-cost formulary
medication is defined as one in
which the acquisition cost for the
expected course of therapy exceeds $5,000. If the acquisition
cost for the expected course is
$5,000 or greater, the pharmacist
processing the order will contact
the Director of Pharmacy Services or the Chair of the Pharmacy and Therapeutics Committee to obtain second-level administrative approval prior to
processing the order.
Attending-level members of the
medical or dental faculty may
request that a medication or dosage form be added to or deleted
from the formulary. Formulary
request forms may be obtained
from the Drug Information Center at extension 2-3896, by email (druginfo@musc.edu), or
online on the formulary web site.
The link to the to the form is located above the search area. The

completed form must be countersigned by the appropriate department chair or division chief.
Once a request is received, a review is prepared by the Drug Information Center staff for presentation to the Pharmacy and Therapeutics Committee. Reviews are
based on published medical literature and focus on the efficacy,
safety, tolerability, and economic
impact of the agent. Following
the presentation and discussion, a
vote is taken. Actions taken by
the Pharmacy and Therapeutics
Committee are generally given an
effective date on or about the 15th
day of the following month. Any
action deemed necessary for patient safety becomes effective immediately.
Following each meeting, requesters are notified in writing of the
Committee’s actions. Changes to
the formulary are published each
month in Pharmacy and Therapeutics Update. Questions regarding the formulary should be referred to Kelli Garrison at 2-4682
or garrisok@musc.edu.

Clinical Pharmacy On-call Services
The Department of Pharmacy Services provides continuous 24-hour
clinical pharmacy coverage. On
weekdays, please consult the pharmacist covering your service. For
nighttime, weekend, and holiday
coverage, please page the clinical
pharmacist on-call.
If you require clinical pharmacy
services and are on a service or
unit that does not have regular
clinical pharmacy coverage,
please page the clinical pharma-

cist on-call or call the Drug
Information Center at extension
2-3896. The clinical pharmacist
on-call can provide the following services:
▪ design and monitor a patient’s
pharmacotherapy regimen
▪ provide pharmacokinetic
consults
▪ follow up on adverse
drug events
▪ provide intensive patient
counseling
▪ provide guidance for initiating

or adjusting parenteral or enteral nutrition
▪ screen for drug-drug or
drug-food interactions.
Clinical pharmacy on-call services
are available for adult, pediatric,
psychiatric, and inpatient family
medicine services. To contact a
clinical pharmacist on-call, go to
http://simonweb.musc.edu and
search “clinical pharmacology”
using the on-call search feature or
call the paging operator at 2-2123.
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Required Elements for
Inpatient and Clinic
Medication Orders

Online Adverse Drug Reaction Reporting
Practitioners are urged to use the
University HealthSystem Consortium Patient Safety Net to report
potential adverse drug reactions
(ADRs).
To access the reporting system
click on the UHC PSN desktop
icon located on all LYNX work
stations and follow the menudriven instructions (see below).
Please include all pertinent details
related to the occurrence including
suspect medication(s), dose(s),
clinical presentation, description
of how the ADR was managed,
and the patient outcome.
The online form is easy
to complete and should
take less than 15 minutes.
If more time is needed,
please remember to extend your time at the top

of the screen. If the time is not
reset, the system will automatically log you off and all your
information will be lost.
ADRs are monitored through the
voluntary reports and through ecode technology. E-codes are
secondary diagnostic codes that
are assigned after discharge. If a
patient experiences an adverse
event that can attributed to a
medication, the encounter will
be coded and investigated.
All ADRs detected through these
mechanism are reported to the
Pharmacy and Therapeutics
Committee for potential
follow-up. If you have
any questions about the
ADR system, please
contact the Drug Information Center at extension 2-3896.

For a medication order to be considered complete and valid, the
Medical Executive Committee has
mandated that the following criteria be met:
Regarding Orders for
Adult Patients
•
•
•

•

Prohibited abbreviations
must not be used
Date and time order must
be written
Weight in kilograms required for medications that
are dosed based on weight
(eg, chemotherapy)
Medication name
▪ generic name preferred,
▪ specify salt form
(eg, potassium chloride, potassium phosphate)
▪ chemical names for electro-

Drug Information Services
The Drug Information Center provides evidence-based answers to
the professional staff’s medication-related questions.
In 2006, the Drug Information
Center responded to more than
1,800 questions received from
physicians, pharmacists, nurses,
other health care professionals,
and consumers+
The mission of the Center is to
promote the best practices
regarding medication usage. The
principle activities of the Drug
Information Center include the
following:

▪ Providing responses to drug–
related questions that support
patient care and research
activities

▪ Publishing Pharmacy and
Therapetuics Update: Drug
Information for Health Care
Professionals

▪ Coordinating the Adverse
Drug Event Reporting
Program

▪ Developing
policies

▪ Coordinating the Medication
Utilization Evaluation Program
▪ Preparing formulary
monographs and class reviews
to guide the Pharmacy and
Therapeutics Committee in its
formulary decisions
▪ Providing
inservices

educational

medication

use

▪ Providing therapeutic
alternatives in response to
medication shortages
The Drug Information Center is
open Monday through Friday,
9:00 AM to 5:30 PM.
The
telephone number to the Center is
792-3896 or you can email your
request to druginfo@musc.edu.
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•
•

•

•
•

•
•

lytes are acceptable, except
for MgSO4
Dose
Dosage units
▪ metric units only
▪ do not use ampules, tablets,
bottles as the only dosage
unit.
▪ specify the concentration
(eg, mg/mL), if applicable
Diluent
▪ specify if requiring diluent
other than the standard (ie,
5% dextrose or 0.9% NaCl)
Route of administration
Frequency or interval
▪ all orders for PRN medications must include an interval and an indication
▪ do not use range orders with
variable dosing frequencies
(eg, q 4 - 6hours)
Signature/credentials
Pager number of prescriber
Regarding Orders for
Pediatric Patients
[< 17 years of age
(except for obstetric patients)]

•

Prohibited abbreviations
must not be used
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•
•
•

•

•

Date and time order must
be written
Weight in kilograms or
grams on ALL orders
Medication name
▪ generic name preferred
▪ specify salt form
(eg, potas-sium chloride,
potassium phosphate)
▪ chemical names for electrolytes are acceptable, except for MgSO4
Dose
▪ dose/kg/interval required
for all patients weighing
less than 40 kg (eg, mg/kg/
dose or mg/kg/day)
▪ the dose/kg/interval should
be specified for one of the
medications in combination preparations
▪ elemental preparations (eg,
iron, zinc) should be ordered based on the desired
dose of the element, not the
salt
Dosage units
▪ metric units only
▪ do not use ampules, tablets,
bottles as the only dosage
unit.
▪ specify the concentration

(eg, mg/mL), if applicable
•

Diluent
▪ specify if the diluent required is outside of the standard (ie, 5% dextrose or
0.9% NaCl )
Route of administration
Frequency or interval
▪ all orders for PRN medications must include an interval and an indication
▪ do not use range orders with
variable dosing frequencies
(eg, q 4 - 6 hours)
Signature/credentials
Pager number of prescriber
3

•
•

•
•

For more detailed information regarding medication orders, please
refer to the medication orders policy C-78 located in the MUSC
Medical Center Clinical Policy
Manual.
The link to the guidelines can be
found on the online formulary under Medication Safety Resources
( www.formularyproducts.com/musc ).
This document also contains the
list of prohibited abbreviations.

Did You Know...
The Food and Drug Administration (FDA) announced that it is
permitting the restricted use of
tegaserod maleate (Zelnorm®) under a treatment investigational
new drug (IND) protocol to treat
irritable bowel syndrome with
constipation (IBS-C) and chronic
idiopathic constipation (CIC) in
women younger than 55 who meet
specific guidelines. Treatment
IND allows patients with a serious

or life-threatening disease or
condition who are not enrolled in
a clinical trial to be treated with
a drug not approved by the FDA.
Generally, such use is allowed
within guidelines when no comparable or satisfactory alternative drug or therapy is available.
In addition to the age and gender
restrictions, the IND protocol for
tegaserod limits use of the drug

to those with IBS-C or CIC whose
physicians decide the drug is
medically necessary. Patients
must sign consent materials to ensure they are fully informed of the
potential risks and benefits of
tegaserod.
If a patient is approved for the
treatment IND protocol the manufacturer will provide the medication at no cost to the patient.
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Each patient will be provided with
a 1-month supply of tegaserod 6
mg. Reauthorization from the physician will be required for an additional supply of tegaserod to be
sent to the patient.
The length of the treatment IND
program is not know at this time.
The manufacturer will continue to
work with FDA on the safety and
benefit assessment of tegaserod.
Key inclusion criteria include the
following:
▪ Women less than 55 years
▪ Patients currently suffering with
IBS-C or CIC
▪ No satisfactory response to other
available treatments and/or pa-

tients who had satisfactory improvement of their symptoms
with prior tegaserod treatment
Key exclusion criteria include
the following:
▪ History or current diagnosis of
cardiovascular ischemic disease
▪ Symptoms suggestive of cardiovascular ischemic disease
▪ Presence of any cardiovascular
risk factors according to NIH
guidelines
▪ Uncompensated depression or
anxiety or suicidal ideation or
behavior

its marketing and sales because a
safety analysis found a higher
chance of heart attack, stroke, and
unstable angina compared with
placebo.
Tegaserod is still considered nonformulary on the MUSC-MC Formulary of Accepted Drugs. Approval for use in the inpatient setting would also need to obtained
from the Pharmacy and Therapeutics Committee.
Physicians who are treating patients with IBS-C or CIC and who
meet the IND criteria should contact Novartis at 888-669-6682 or
866-248-1348.

In March 2007, FDA the manufacturer of tegaserod, to suspend

FORMULARY UPDATE FOR JUNE 2007
The Pharmacy and Therapeutics
Committee recently approved the
actions listed below. The formulary effective date was July 16,
2007.
Addition:
Thyrotropin alfa (Thyrogen®)
An adjunctive diagnostic tool for
use in serum thyrogobulin testing
with or without radioiodine imaging in the follow-up of patients
with well-differentiated thyroid
cancer.
1.1 mg vials
Line Extensions:
Permethrin (Elimite®) 5% cream
60-g tubes
Deletions:
Lindane 1% lotion and
1% shampoo
Procainamide
375-mg tablets

Automatic Therapeutic Substitution (ATS) Protocols:
The protocol are located on the
Formulary and Drug Information Resources Web page.
(www.formularyproductions.com/musc)
Orders for paliperidone
(Invega®) will be switched to
risperidone (Risperidal®) using
preprinted dosing conversion
guidelines.
Risperidone has
more options for dosing (ie,
strengths), is more bioavailable,
has more indications, and is less
expensive than paliperidone.
Orders received for levofloxacin
(Levaquin®) will be changed to
either moxifloxacin (Aloxi®) or
ciprofloxacin (Cipro®) using the
dosing conversion guidelines.
Orders will be changed to either
moxifloxacin or ciprofloxacin
based on the indication for use.
Moxifloxacin (PO or IV) will be

substituted in place of levofloxacin for respiratory tract or skin/
soft tissue infections, and ciprofloxacin will be substituted for
urinary tract, serious, or nosocomial pneumonia infections. Additionally, renal dosing guidelines
for ciprofloxacin can be found on
the dosing conversion chart.
Updated Charts, Policies, or
Guidelines
1. Community Acquired Pneumonia Pre-printed Order Form
2. Hypertonic Sodium Chloride
or Hypertonic Sodium Chloride/Sodium Acetate Policy
(C-104)
3. MUSC Look-alike/Soundalike Medications list

